Pacira(US:PCRX) Prnewswireยท2025-02-03 10:45Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial strain on the company [1]. Summary by Sections Legal Issues - Pacira's U.S. Patent No. 11,033,495, crucial for its product Exparel, was ruled invalid by the court, impacting approximately 80% of the company's revenue [1]. - The lawsuit against eVenus for patent infringement resulted in the court's decision that eVenus is not infringing on Pacira's patent [1]. Stock Performance - Following the announcement of the patent invalidation, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for potential lead plaintiff appointment in the class action lawsuit [2]. - The deadline for shareholders to seek lead plaintiff status is March 14, 2025, and there is no cost to participate in the case [2].